Benserazide
- Generic Name
- Benserazide
- Brand Names
- Prolopa
- Drug Type
- Small Molecule
- Chemical Formula
- C10H15N3O5
- CAS Number
- 322-35-0
- Unique Ingredient Identifier
- 762OS3ZEJU
- Background
When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebral tissues. This can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish...
- Indication
The primary therapeutic use for which benserazide is currently indicated for is as a combination therapy with levadopa for the treatment of Parkinson's disease in adults > 25 years of age, with the exception of drug-induced parkinsonism .
...
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 600
- Registration Number
- NCT01568073
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
- Conditions
- Interventions
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 427
- Registration Number
- NCT01227655
- Locations
- 🇵🇹
Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.